Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Erythropoietin/EPO CRISPR/Cas9 KO Plasmid (h): sc-400283
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Erythropoietin/EPO CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the Erythropoietin/EPO genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Erythropoietin/EPO Antibody (7D10): sc-80995
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Erythropoietin/EPO CRISPR/Cas9 KO Plasmid (h) | sc-400283 | 20 µg | $397.00 |
Overview
EPO encodes erythropoietin, a secreted glycoprotein hormone that regulates erythroid progenitor survival, proliferation, and differentiation primarily through EPOR-mediated JAK2/STAT5 signaling, with additional input from PI3K/AKT and MAPK pathways. In adult physiology, EPO production is tightly controlled by oxygen sensing via HIF transcriptional programs, linking hypoxia to systemic red blood cell homeostasis. Dysregulated EPO/EPOR axis activity is relevant to mechanisms underlying anemia and hypoxia-associated responses, and it is frequently examined as part of broader studies of iron metabolism, inflammation, and tissue oxygenation. Because EPO is a secreted factor, its gene regulation and downstream signaling effects are also useful readouts for transcriptional control, cytokine signaling cross-talk, and cellular adaptation to low-oxygen stress.
Erythropoietin/EPO CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the EPO gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the EPO together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the EPO open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Erythropoietin/EPO protein expression.
This CRISPR knockout system enables efficient generation of EPO-deficient cell models for investigation of Erythropoietin/EPO signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting EPO exon(s) critical for Erythropoietin/EPO function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple EPO genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by Erythropoietin/EPO CRISPR/Cas9 KO Plasmid (h) and Erythropoietin/EPO CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the EPO locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by Erythropoietin/EPO HDR Plasmid (h) and Erythropoietin/EPO HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by EPO homology arms to support homology-directed repair at defined EPO target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.